RxDoctor Payments Data

Michael Derrick, MD

Pediatric Allergy/Immunology · Murfreesboro, TNNPI 1275828717

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Sanofi at 26.2% of the total. 2025 is the largest year on record at $968, 4.3 times the $225 reported in 2022.

$2,600in general payments, 2019–2025

Across 120 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$682
  • AstraZeneca$536
  • ARS Pharmaceuticals Operations, Inc.$245
  • GSK$235
  • Novartis$164
  • Grifols USA, LLC$141
  • plus $597 from 14 others

What the payments were for

  • Food & beverage$2,52297%
  • Education$793%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few pediatric allergy/immunology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$16,024
Medicare patients
47
Services billed
1,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Epinephrine19$4,038
Azelastine Hcl24$913
Fluticasone Propionate27$329
Albuterol Sulfate HfaAlbuterol Sulfate17$234
Ipratropium Bromide13$160
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$124
Famotidine14$119
Prednisone14$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$17$4,03819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric allergy/immunology providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other pediatric allergy/immunology in Murfreesboro

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →